Skip to main content
SpringerLink
Log in

Genetic Evaluation of Familial Cardiomyopathy

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Hereditary forms of hypertrophic, dilated, restrictive, and right ventricular cardiomyopathies are frequently seen. Patterns of inheritance include autosomal dominant, autosomal recessive, X-linked, and matrilinear. Recognition of the mode of inheritance facilitates proper clinical screening of family members in subsequent generations. Report of successful sequence analysis of the human genome 7 years ago has resulted in widespread translation of genomic information into clinical applications. As technologic advances in high throughput sequence determination continue to evolve, an era of personalized medicine based on genomic data is highly anticipated. Today, clinical genetic testing is available for most monogenic forms of cardiomyopathy and the demand among patients and families is increasing. However, physicians and patients should consider the benefits and limitations of such testing. This review will focus on inherited forms of cardiomyopathy, detailing the currently available genetic tests, as well as benefits, limitations, and possible outcomes of such testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mestroni, L., Rocco, C., Gregori, D., Sinagra, G., Di Lenarda, A., Miocic, S., et al. (1999). Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. Journal of the American College of Cardiology, 34(1), 181–190.

    Article  PubMed  CAS  Google Scholar 

  2. Nussbaum, R. L., McInnes, R. R., & Willard, H. F. (2001). Thompson & Thompson genetics in medicine. Philadelphia, PA: Saunders.

    Google Scholar 

  3. Grosse, S. D., & Khoury, M. J. (2006). What is the clinical utility of genetic testing? Genetics in Medicine, 8(7), 448–450.

    Article  PubMed  Google Scholar 

  4. Holtzman, N. A. (2006). What role for public health in genetics and vice versa? Community Genetics, 9(1), 8–20.

    Article  PubMed  Google Scholar 

  5. Expert-Group, E. (2004). Ethical, legal and social implications of genetic testing. Bulletin of Medical Ethics, 204, 9–11.

    Google Scholar 

  6. Jarcho, J. A., McKenna, W., Pare, J. A., Solomon, S. D., Holcombe, R. F., Dickie, S., et al. (1989). Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. New England Journal of Medicine, 321(20), 1372–1378.

    PubMed  CAS  Google Scholar 

  7. Geisterfer-Lowrance, A. A., Kass, S., Tanigawa, G., Vosberg, H. P., McKenna, W., Seidman, C. E., et al. (1990). A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell, 62(5), 999–1006.

    Article  PubMed  CAS  Google Scholar 

  8. van Driest, S. L., Ommen, S. R., Tajik, A. J., Gersh, B. J., & Ackerman, M. J. (2005). Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clinic Proceedings, 80(6), 739–744.

    Article  PubMed  Google Scholar 

  9. Alcalai, R., Seidman, J. G., & Seidman, C. E. (2008). Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. Journal of Cardiovascular Electrophysiology, 19(1), 104–110.

    PubMed  Google Scholar 

  10. Frischmeyer, P. A., & Dietz, H. C. (1999). Nonsense-mediated mRNA decay in health and disease. Human Molecular Genetics, 8(10), 1893–1900.

    Article  PubMed  CAS  Google Scholar 

  11. Van Driest, S. L., Vasile, V. C., Ommen, S. R., Will, M. L., Tajik, A. J., Gersh, B. J., et al. (2004). Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 44(9), 1903–1910.

    Article  PubMed  CAS  Google Scholar 

  12. Richard, P., Charron, P., Carrier, L., Ledeuil, C., Cheav, T., Pichereau, C., et al. (2003). Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation, 107(17), 2227–2232.

    Article  PubMed  Google Scholar 

  13. Vasile, V. C., Will, M. L., Ommen, S. R., Edwards, W. D., Olson, T. M., & Ackerman, M. J. (2006). Identification of a metavinculin missense mutation, R975W, associated with both hypertrophic and dilated cardiomyopathy. Biochemical and Molecular Medicine, 87(2), 169–174.

    CAS  Google Scholar 

  14. Bos, J. M., Poley, R. N., Ny, M., Tester, D. J., Xu, X., Vatta, M., et al. (2006). Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. Molecular Genetics and Metabolism, 88(1), 78–85.

    Article  PubMed  CAS  Google Scholar 

  15. Carniel, E., Taylor, M. R. G., Sinagra, G., Di Lenarda, A., Ku, L., Fain, P. R., et al. (2005). Alpha-Myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation, 112(1), 54–59.

    Article  PubMed  CAS  Google Scholar 

  16. Osio, A., Tan, L., Chen, S. N., Lombardi, R., Nagueh, S. F., Shete, S., et al. (2007). Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circulation Research, 100(6), 766–768.

    Article  PubMed  CAS  Google Scholar 

  17. Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., et al. (2006). High incidence of later-onset fabry disease revealed by newborn screening. American Journal of Human Genetics, 79(1), 31–40.

    Article  PubMed  CAS  Google Scholar 

  18. Desnick, R. J., & Banikazemi, M. (2006). Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Néphrologie & Thérapeutique, 2(Suppl 2), S172–185.

    CAS  Google Scholar 

  19. Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967). Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. New England Journal of Medicine, 276(21), 1163–1167.

    PubMed  CAS  Google Scholar 

  20. Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., et al. (2003). Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Annals of Internal Medicine, 138(4), 338–346.

    PubMed  Google Scholar 

  21. Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., et al. (2004). Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation, 110(9), 1047–1053.

    Article  PubMed  CAS  Google Scholar 

  22. Banikazemi, M., Bultas, J., Waldek, S., Wilcox, W. R., Whitley, C. B., McDonald, M., et al. (2007). Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Annals of Internal Medicine, 146(2), 77–86.

    PubMed  Google Scholar 

  23. Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., et al. (2000). Infusion of alpha -galactosidase a reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proceedings of the National Academy of Sciences, 97(1), 365–370.

    Article  CAS  Google Scholar 

  24. Kwon, D. H., Setser, R. M., Popovic, Z. B., Thamilarasan, M., Sola, S., Schoenhagen, P., et al. (2008). Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. International Journal of Cardiac Imaging, DOI 10.1007/s10554-008-9292-6.

  25. Maron, B. J., Spirito, P., Shen, W. K., Haas, T. S., Formisano, F., Link, M. S., et al. (2007). Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA, 298(4), 405–412.

    Article  PubMed  CAS  Google Scholar 

  26. Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., et al. (2006). ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation, 114(10), e385–e484.

    Article  PubMed  Google Scholar 

  27. Charron, P., Dubourg, O., Desnos, M., Bennaceur, M., Carrier, L., Camproux, A. -C., et al. (1998). Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac Myosin-binding protein C gene. Circulation, 97(22), 2230–2236.

    PubMed  CAS  Google Scholar 

  28. Erdmann, J., Raible, J. O., Maki-Abadi, J., Hummel, M., Hammann, J., Wollnik, B., et al. (2001). Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 38(2), 322–330.

    Article  PubMed  CAS  Google Scholar 

  29. Alders, M., Jongbloed, R., Deelen, W., van den Wijngaard, A., Doevendans, P., Ten Cate, F., et al. (2003). The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. European Heart Journal, 24(20), 1848–1853.

    Article  PubMed  CAS  Google Scholar 

  30. Michels, V. V., Moll, P. P., Miller, F. A., Tajik, A. J., Chu, J. S., Driscoll, D. J., et al. (1992). The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. New England Journal of Medicine, 326(2), 77–82.

    PubMed  CAS  Google Scholar 

  31. Grunig, E., Tasman, J. A., Kucherer, H., Franz, W., Kubler, W., & Katus, H. A. (1998). Frequency and phenotypes of familial dilated cardiomyopathy. Journal of the American College of Cardiology, 31(1), 186–194.

    Article  PubMed  CAS  Google Scholar 

  32. Baig, M. K., Goldman, J. H., Caforio, A. L., Coonar, A. S., Keeling, P. J., & McKenna, W. J. (1998). Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease. Journal of the American College of Cardiology, 31(1), 195–201.

    Article  PubMed  CAS  Google Scholar 

  33. Cheitlin, M. D., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., Davis, J. L., et al. (2003). ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 108(9), 1146–1162.

    Article  PubMed  Google Scholar 

  34. Hoffman, E. P., Brown Jr., R. H., & Kunkel, L. M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51(6), 919–928.

    Article  PubMed  CAS  Google Scholar 

  35. Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50(3), 509–517.

    Article  PubMed  CAS  Google Scholar 

  36. Ahn, A. H., & Kunkel, L. M. (1993). The structural and functional diversity of dystrophin. Nature Genetics, 3(4), 283–291.

    Article  PubMed  CAS  Google Scholar 

  37. Olson, T. M., Michels, V. V., Thibodeau, S. N., Tai, Y. S., & Keating, M. T. (1998). Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science, 280(5364), 750–752.

    Article  PubMed  CAS  Google Scholar 

  38. Fatkin, D., MacRae, C., Sasaki, T., Wolff, M. R., Porcu, M., Frenneaux, M., et al. (1999). Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. New England Journal of Medicine, 341(23), 1715–1724.

    Article  PubMed  CAS  Google Scholar 

  39. van Tintelen, J. P., Hofstra, R. M. W., Katerberg, H., Rossenbacker, T., Wiesfeld, A. C. P., du Marchie Sarvaas, G. J., et al. (2007). High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. American Heart Journal, 154(6), 1130–1139.

    Article  PubMed  CAS  Google Scholar 

  40. Perrot, A., Sigusch, H. H., Nagele, H., Genschel, J., Lehmkuhl, H., Hetzer, R., et al. (2006). Genetic and phenotypic analysis of dilated cardiomyopathy with conduction system disease: Demand for strategies in the management of presymptomatic lamin A/C mutant carriers. European Journal of Heart Failure, 8(5), 484–493.

    Article  PubMed  CAS  Google Scholar 

  41. Taylor, M. R. G., Fain, P. R., Sinagra, G., Robinson, M. L., Robertson, A. D., Carniel, E., et al. (2003). Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. Journal of the American College of Cardiology, 41(5), 771–780.

    Article  PubMed  CAS  Google Scholar 

  42. Becane, H. M., Bonne, G., Varnous, S., Muchir, A., Ortega, V., Hammouda, E. H., et al. (2000). High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing and Clinical Electrophysiology, 23(11 Pt 1), 1661–1666.

    Article  PubMed  CAS  Google Scholar 

  43. Meune, C., Van Berlo, J. H., Anselme, F., Bonne, G., Pinto, Y. M., & Duboc, D. (2006). Primary prevention of sudden death in patients with lamin A/C gene mutations. New England Journal of Medicine, 354(2), 209–210.

    Article  PubMed  CAS  Google Scholar 

  44. van Berlo, J. H., de Voogt, W. G., van der Kooi, A. J., van Tintelen, J. P., Bonne, G., Yaou, R. B., et al. (2005). Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? Journal of Molecular Medecine, 83(1), 79–83.

    Article  CAS  Google Scholar 

  45. Decaudain, A., Vantyghem, M. C., Guerci, B., Hecart, A. C., Auclair, M., Reznik, Y., et al. (2007). New metabolic phenotypes in laminopathies: LMNA mutations in patients with severe metabolic syndrome. Journal of Clinical Endocrinology and Metabolism, 92(12), 4835–4844.

    Article  PubMed  CAS  Google Scholar 

  46. Kamisago, M., Sharma, S. D., DePalma, S. R., Solomon, S., Sharma, P., McDonough, B., et al. (2000). Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. New England Journal of Medicine, 343(23), 1688–1696.

    Article  PubMed  CAS  Google Scholar 

  47. Seidman, J. G., & Seidman, C. (2001). The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell, 104(4), 557–567.

    Article  PubMed  CAS  Google Scholar 

  48. Wang, Q., Shen, J., Splawski, I., Atkinson, D., Li, Z., Robinson, J. L., et al. (1995). SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell, 80(5), 805–811.

    Article  PubMed  CAS  Google Scholar 

  49. Bezzina, C., Veldkamp, M. W., van den Berg, M. P., Postma, A. V., Rook, M. B., Viersma, J. -W., et al. (1999). A single Na+ channel mutation causing both long-QT and brugada syndromes. Circulation Research, 85(12), 1206–1213.

    PubMed  CAS  Google Scholar 

  50. Probst, V., Kyndt, F., Potet, F., Trochu, J. N., Mialet, G., Demolombe, S., et al. (2003). Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease. Journal of the American College of Cardiology, 41(4), 643–652.

    Article  PubMed  CAS  Google Scholar 

  51. Schott, J. -J., Alshinawi, C., Kyndt, F., Probst, V., Hoorntje, T. M., Hulsbeek, M., et al. (1999). Cardiac conduction defects associate with mutations in SCN5A. Nature Genetics, 23(1), 20–21.

    Google Scholar 

  52. McNair, W. P., Ku, L., Taylor, M. R. G., Fain, P. R., Dao, D., Wolfel, E., et al. (2004). SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation, 110(15), 2163–2167.

    Article  PubMed  CAS  Google Scholar 

  53. Olson, T. M., Michels, V. V., Ballew, J. D., Reyna, S. P., Karst, M. L., Herron, K. J., et al. (2005). Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA, 293(4), 447–454.

    Article  PubMed  CAS  Google Scholar 

  54. Bienengraeber, M., Olson, T. M., Selivanov, V. A., Kathmann, E. C., O’Cochlain, F., Gao, F., et al. (2004). ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nature Genetics, 36(4), 382–387.

    Article  PubMed  CAS  Google Scholar 

  55. Schonberger, J., Wang, L., Shin, J. T., Kim, S. D., Depreux, F. F., Zhu, H., et al. (2005). Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nature Genetics, 37(4), 418–422.

    Article  PubMed  CAS  Google Scholar 

  56. Schonberger, J., Levy, H., Grunig, E., Sangwatanaroj, S., Fatkin, D., MacRae, C., et al. (2000). Dilated cardiomyopathy and sensorineural hearing loss: a heritable syndrome that maps to 6q23–24. Circulation, 101(15), 1812–1818.

    PubMed  CAS  Google Scholar 

  57. McKenna, W. J., Thiene, G., Nava, A., Fontaliran, F., Blomstrom-Lundqvist, C., Fontaine, G., et al. (1994). Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task force of whe Working group myocardial and pericardial disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. British Heart Journal, 71(3), 215–218.

    Article  PubMed  CAS  Google Scholar 

  58. Norman, M., Simpson, M., Mogensen, J., Shaw, A., Hughes, S., Syrris, P., et al. (2005). Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation, 112(5), 636–642.

    Article  PubMed  CAS  Google Scholar 

  59. Sen-Chowdhry, S., Syrris, P., Ward, D., Asimaki, A., Sevdalis, E., & McKenna, W. J. (2007). Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation, 115(13), 1710–1720.

    Article  PubMed  Google Scholar 

  60. Coonar, A. S., Protonotarios, N., Tsatsopoulou, A., Needham, E. W., Houlston, R. S., Cliff, S., et al. (1998). Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation, 97(20), 2049–2058.

    PubMed  CAS  Google Scholar 

  61. McKoy, G., Protonotarios, N., Crosby, A., Tsatsopoulou, A., Anastasakis, A., Coonar, A., et al. (2000). Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). The Lancet, 355(9221), 2119–2124.

    Article  CAS  Google Scholar 

  62. Rampazzo, A., Nava, A., Malacrida, S., Beffagna, G., Bauce, B., Rossi, V., et al. (2002). Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. American Journal of Human Genetics, 71(5), 1200–1206.

    Article  PubMed  CAS  Google Scholar 

  63. Gerull, B., Heuser, A., Wichter, T., Paul, M., Basson, C. T., McDermott, D. A., et al. (2004). Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nature Genetics, 36(11), 1162–1164.

    Article  PubMed  CAS  Google Scholar 

  64. Awad, M. M., Dalal, D., Cho, E., Amat-Alarcon, N., James, C., Tichnell, C., et al. (2006). DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. American Journal of Human Genetics, 79(1), 136–142.

    Article  PubMed  CAS  Google Scholar 

  65. Heuser, A., Plovie, E. R., Ellinor, P. T., Grossmann, K. S., Shin, J. T., Wichter, T., et al. (2006). Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy. American Journal of Human Genetics, 79(6), 1081–1088.

    Article  PubMed  CAS  Google Scholar 

  66. Awad, M. M., Calkins, H., & Judge, D. P. (2008). Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, DOI 10.1038/ncpcardio1182.

  67. Garcia-Gras, E., Lombardi, R., Giocondo, M. J., Willerson, J. T., Schneider, M. D., Khoury, D. S., et al. (2006). Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. Journal of Clinical Investigation, 116(7), 2012–2021.

    Article  PubMed  CAS  Google Scholar 

  68. Oxford, E. M., Musa, H., Maass, K., Coombs, W., Taffet, S. M., & Delmar, M. (2007). Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells. Circulation Research, 101(7), 703–711.

    Article  PubMed  CAS  Google Scholar 

  69. Saffitz, J. E., Hames, K. Y., & Kanno, S. (2007). Remodeling of gap junctions in ischemic and nonischemic forms of heart disease. Journal of Membrane Biology, 218(1–3), 65–71.

    Article  PubMed  CAS  Google Scholar 

  70. Dalal, D., Molin, L. H., Piccini, J. P., Tichnell, C., James, C., Bomma, C., et al. (2006). Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation, 113(13), 1641–1649.

    Article  PubMed  CAS  Google Scholar 

  71. Dalal, D., James, C., Devanagondi, R., Tichnell, C., Tucker, A., Prakasa, K., et al. (2006). Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Journal of the American College of Cardiology, 48(7), 1416–1424.

    Article  PubMed  CAS  Google Scholar 

  72. Syrris, P., Ward, D., Asimaki, A., Evans, A., Sen-Chowdhry, S., Hughes, S. E., et al. (2007). Desmoglein-2 mutations in arrhythmogenic right ventricular cardiomyopathy: a genotype-phenotype characterization of familial disease. European Heart Journal, 28(5), 581–588.

    Article  PubMed  CAS  Google Scholar 

  73. Syrris, P., Ward, D., Asimaki, A., Sen-Chowdhry, S., Ebrahim, H. Y., Evans, A., et al. (2006). Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation, 113(3), 356–364.

    Article  PubMed  CAS  Google Scholar 

  74. Nava, A., Bauce, B., Basso, C., Muriago, M., Rampazzo, A., Villanova, C., et al. (2000). Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. Journal of the American College of Cardiology, 36(7), 2226–2233.

    Article  PubMed  CAS  Google Scholar 

  75. Sen-Chowdhry, S., Syrris, P., & McKenna, W. J. (2007). Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Journal of the American College of Cardiology, 50(19), 1813–1821.

    Article  PubMed  CAS  Google Scholar 

  76. Bhuiyan, Z. A., van den Berg, M. P., van Tintelen, J. P., Bink-Boelkens, M. T. E., Wiesfeld, A. C. P., Alders, M., et al. (2007). Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation, 116(14), 1569–1576.

    Article  PubMed  Google Scholar 

  77. Schwartz, M., & Duno, M. (2004). Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method. Genetic Testing, 8(4), 361–367.

    Article  PubMed  CAS  Google Scholar 

  78. Gille, J. J., Hogervorst, F. B., Pals, G., Wijnen, J. T., van Schooten, R. J., Dommering, C. J., et al. (2002). Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. British Journal of Cancer, 87(8), 892–897.

    Article  PubMed  CAS  Google Scholar 

  79. van Tintelen, J. P., Tio, R. A., Kerstjens-Frederikse, W. S., van Berlo, J. H., Boven, L. G., Suurmeijer, A. J. H., et al. (2007). Severe myocardial fibrosis caused by a deletion of the 5¢ end of the lamin A/C gene. Journal of the American College of Cardiology, 49(25), 2430–2439.

    Article  PubMed  CAS  Google Scholar 

  80. Hodgkinson, K. A., Parfrey, P. S., Bassett, A. S., Kupprion, C., Drenckhahn, J., Norman, M. W., et al. (2005). The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). Journal of the American College of Cardiology, 45(3), 400–408.

    Article  PubMed  Google Scholar 

  81. Beffagna, G., Occhi, G., Nava, A., Vitiello, L., Ditadi, A., Basso, C., et al. (2005). Regulatory mutations in transforming growth factor-[beta]3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovascular Research, 65(2), 366–373.

    Article  PubMed  CAS  Google Scholar 

  82. Awad, M. M., Dalal, D., Tichnell, C., James, C., Tucker, A., Abraham, T., et al. (2006). Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2. Human Mutation, 27(11), 1157.

    Article  PubMed  Google Scholar 

  83. Pilichou, K., Nava, A., Basso, C., Beffagna, G., Bauce, B., Lorenzon, A., et al. (2006). Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation, 113(9), 1171–1179.

    Article  PubMed  CAS  Google Scholar 

  84. Mogensen, J., Kubo, T., Duque, M., Uribe, W., Shaw, A., Murphy, R., et al. (2003). Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 111(2), 209–216.

    PubMed  CAS  Google Scholar 

  85. Peddy, S. B., Vricella, L. A., Crosson, J. E., Oswald, G. L., Cohn, R. D., Cameron, D. E., et al. (2006). Infantile restrictive cardiomyopathy resulting from a mutation in the cardiac troponin T gene. Pediatrics, 117(5), 1830–1833.

    Article  PubMed  Google Scholar 

  86. Ware, S. M., Quinn, M. E., Ballard, E. T., Miller, E., Uzark, K., & Spicer, R. L. (2008). Pediatric restrictive cardiomyopathy associated with a mutation in beta-myosin heavy chain. Clinical Genetics, 73(2), 165–170.

    PubMed  CAS  Google Scholar 

  87. Monserrat, L., Hermida-Prieto, M., Fernandez, X., Rodriguez, I., Dumont, C., Cazon, L., et al. (2007). Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. European Heart Journal, 28(16), 1953–1961.

    Article  PubMed  CAS  Google Scholar 

  88. Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., et al. (1997). Variant-sequence transthyretin (Isoleucine 122) in late-onset cardiac amyloidosis in black Americans. New England Journal of Medicine, 336(7), 466–473.

    Article  PubMed  CAS  Google Scholar 

  89. Arbustini, E., Morbini, P., Grasso, M., Fasani, R., Verga, L., Bellini, O., et al. (1998). Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits. Journal of the American College of Cardiology, 31(3), 645–653.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors acknowledge support for this work from the Montgomery Heart Foundation, the JHU Ladies in Red, and the Jeff Cooper CARE Foundation.

Author information

Authors and Affiliations

  1. Division of Cardiology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 1049, Baltimore, MD, 21205, USA

    Daniel P. Judge & Nicole M. Johnson

Authors
  1. Daniel P. Judge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole M. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel P. Judge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Judge, D.P., Johnson, N.M. Genetic Evaluation of Familial Cardiomyopathy. J. of Cardiovasc. Trans. Res. 1, 144–154 (2008). https://doi.org/10.1007/s12265-008-9025-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-008-9025-1

Keywords

Search

Navigation